Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 189Neoplasm Metastasis 24Neoplasms 23Ovarian Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 7Endometrial Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Prostatic Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Head and Neck Neoplasms 6Carcinoma, Renal Cell 6Breast Diseases 6Recurrence 5Medulloblastoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Triple Negative Breast Neoplasms 4Sarcoma, Ewing 4Neoplasms by Site 4Lymphoma, Mantle-Cell 4Liposarcoma 4Glioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

Pemetrexed 9Nivolumab 8Cisplatin 8Carboplatin 8pembrolizumab 7130-nm albumin-bound paclitaxel 7Gemcitabine 6padeliporfin 5durvalumab 5Paclitaxel 5Bevacizumab 5palbociclib 4napabucasin 4atezolizumab 4Irinotecan 4Fulvestrant 4Fluorouracil 4Drug Therapy 4Cyclophosphamide 4ribociclib 3osimertinib 3cobimetinib 3alectinib 3abemaciclib 3Trastuzumab 3Sunitinib 3Radiosurgery 3Mitomycin 3Docetaxel 3Cetuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms by Site × palbociclib × Clear all
NCT05768139 2026-05-22

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT04964934 2026-04-21

SERENA-6

AstraZeneca

Phase 3 Active not recruiting
315 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

NiKang Therapeutics, Inc.

Phase 2 Terminated
18 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT04711252 2025-10-14

SERENA-4

AstraZeneca

Phase 3 Active not recruiting
1,370 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡